Search research articles
Contact Us
Filters
Showing results (231-240 of 255) with videos related to
Page
of 26
Sort By:
Cancers
|
October 30, 2020
Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study
Ulrich-Frank Pape, Stefan Kasper, Johannes Meiler, et al.
Pancreas
|
April 2, 2010
Optimal timing of oral refeeding in mild acute pancreatitis: results of an open randomized multicenter trial
Niels Teich, Ali Aghdassi, Julia Fischer, et al.
British Journal of Cancer
|
January 19, 2013
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer
A Atmaca, S-E Al-Batran, D Werner, et al.
The Lancet. Gastroenterology & Hepatology
|
August 19, 2024
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
Klara Dorman, Stefan Boeck, Karel Caca, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M Haas, J T Siveke, M Schenk, et al.
Zeitschrift Fur Gastroenterologie
|
March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]
M P Ebert, C Auernhammer, K Caca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2021
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
Dominik Paul Modest, Meinolf Karthaus, Stefan Fruehauf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
Hans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, et al.
Eclinicalmedicine
|
January 13, 2025
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial
Arndt Stahler, Meinolf Karthaus, Stefan Fruehauf, et al.
ESMO Open
|
July 13, 2023
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
K Heinrich, M Karthaus, S Fruehauf, et al.
Page
of 26
Search research articles
Search
Showing results (231-240 of 255) with videos related to
Sort By:
Page
of 26
Cancers
|
October 30, 2020
Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study
Ulrich-Frank Pape, Stefan Kasper, Johannes Meiler, et al.
Pancreas
|
April 2, 2010
Optimal timing of oral refeeding in mild acute pancreatitis: results of an open randomized multicenter trial
Niels Teich, Ali Aghdassi, Julia Fischer, et al.
British Journal of Cancer
|
January 19, 2013
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer
A Atmaca, S-E Al-Batran, D Werner, et al.
The Lancet. Gastroenterology & Hepatology
|
August 19, 2024
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
Klara Dorman, Stefan Boeck, Karel Caca, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M Haas, J T Siveke, M Schenk, et al.
Zeitschrift Fur Gastroenterologie
|
March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]
M P Ebert, C Auernhammer, K Caca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2021
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
Dominik Paul Modest, Meinolf Karthaus, Stefan Fruehauf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD
Hans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, et al.
Eclinicalmedicine
|
January 13, 2025
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial
Arndt Stahler, Meinolf Karthaus, Stefan Fruehauf, et al.
ESMO Open
|
July 13, 2023
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
K Heinrich, M Karthaus, S Fruehauf, et al.
Page
of 26